Generic Entry

Generic Entry is a regulatory milestone representing the first market introduction of a pharmaceutically equivalent drug product following the expiration of data or market exclusivity protections, distinguished by its reliance on the preexisting safety and efficacy data of the reference innovator product rather than independent clinical demonstration.

137

Publications

7.6K

Citations

319

Authors

183

Institutions

Publications per year

2017–2026

32

Variants

Generic Market Entry

Authors

319

  1. AS
    Aaron S. Kesselheim

    Brigham and Women's Hospital, United States

    7 publications · 155 citations

    7

    h-index

  2. HG
    Henry G. Grabowski

    Duke University, United States

    6 publications · 500 citations

    6

    h-index

  3. PK
    Panos Kanavos

    London School of Economics and Political Science, United Kingdom

    5 publications · 469 citations

    5

    h-index

  4. RF
    Reed F. Beall

    University of Calgary, Canada

    5 publications · 119 citations

    5

    h-index

  5. RG
    Richard G. Frank

    Harvard University, United States

    5 publications · 939 citations

    5

    h-index

1–5 of 319

Venues

  1. SSRN Electronic Journal

    Repository · 14 publications · 341 citations

    11

    h-index

  2. Journal of Health Economics

    5 publications · 459 citations

    5

    h-index

  3. 5

    h-index

  4. National Bureau of Economic Research

    Repository · 5 publications · 318 citations

    5

    h-index

  5. JAMA

    4 publications · 146 citations

    4

    h-index

1–5